ENTITY
Venus Medtech (Hangzhou)

Venus Medtech (Hangzhou) (2500 HK)

111
Analysis
Health Care • China
Venus Medtech is a leading medical device company specializing in transcatheter structural heart valvular therapies. It develops and commercializes innovative solutions for all four heart valves (TAVR, TPVR, TMVR, TTVR) and interventional hypertension treatment. The company was founded in 2009 and is headquartered in Hangzhou, China.
more
•26 Jan 2021 17:18

MicroPort CardioFlow IPO: Valuation Insights

MicroPort aims to raise total net proceeds of $290 million at the mid-point of the IPO price range of HK$11.10-12.20 per share. Overall, we think...

Logo
480 Views
Share
•24 Jan 2021 10:20

MicroPort Cardioflow (微创心通) Pre-IPO: Thoughts on Valuation

We are taking a close look at the Microport Cardioflow’s valuation. We are of the view that the company’s fair value should be around USD 3.0 billion.

Logo
578 Views
Share
•21 Jan 2021 18:57

Venus Medtech (启明医疗) & Peijia Medical (沛嘉医疗) Placement - Take Your Pick

Venus MedTech (2500 HK) is looking to raise up to US$187m in its primary placement. At the same time, Peijia Medical (9996 HK) is looking to raise...

Share
•20 Jan 2021 01:22

MicroPort CardioFlow IPO Initiation: To Save a Life

MicroPort is pre-marketing for an HK IPO to raise $300 million. With a large addressable market opportunity and VitaFlow’s potentially best-in...

Logo
955 Views
Share
•13 Jan 2021 13:49

MicroPort Cardioflow (微创心通) Pre-IPO: Strong Sales Ramp-Up Despite Being Late in Market

The company's first-generation TAVR, VitaFlow, has decent clinical data in terms of efficacy and safety. It was launched two years behind VenusA...

Logo
628 Views
Share
x